Best Inositol Supplements 2026

Myo-Inositol (MI): The Predominant Brain and Tissue Form

Myo-Inositol is the most abundant inositol isomer in human tissue, comprising over 99% of total cellular inositol content in the brain, liver, and most peripheral organs. It functions as a second messenger for insulin, FSH, TSH, and numerous G-protein coupled receptor (GPCR) signaling pathways. In the brain, MI is a critical component of the phosphatidylinositol (PI) cycle — the signaling cascade used by serotonin, dopamine, and norepinephrine receptors to transduce extracellular signals into intracellular responses. This is the mechanism underlying the psychiatric research on high-dose MI supplementation: by restoring PI cycle substrate availability, MI may enhance serotonergic neurotransmission in a manner analogous to selective serotonin reuptake inhibitors (SSRIs) but without receptor-level pharmacological action.

Best for: Mood support, anxiety, panic disorder, OCD, insulin sensitivity, general metabolic health, PCOS (as part of 40:1 combination)

D-Chiro-Inositol (DCI): The Androgen Metabolism Regulator

D-Chiro-Inositol is produced enzymatically from Myo-Inositol by the epimerase enzyme and plays a distinct metabolic role from MI. In insulin-sensitive tissues, DCI-containing inositol phosphoglycans (IPGs) mediate the activation of pyruvate dehydrogenase phosphatase — an enzyme controlling glucose oxidation. DCI also plays a specific role in ovarian steroidogenesis: it inhibits aromatase activity, reducing androgen-to-estrogen conversion, which is relevant in PCOS where excess androgen production contributes to clinical manifestations including hirsutism, acne, and irregular cycles. However, administering DCI alone or in excessive proportions relative to MI has been shown to paradoxically impair oocyte quality — DCI excess in follicular fluid reduces FSH signaling effectiveness. This is why the 40:1 MI:DCI ratio, rather than pure DCI or equal proportions, is the evidence-based formulation for PCOS.

Best for: PCOS (combined with MI in 40:1 ratio), androgen excess, insulin resistance in metabolic syndrome

The 40:1 MI:DCI Combination: Why Ratio Matters

The physiological ratio of MI to DCI in healthy human ovarian follicular fluid is approximately 100:1. In women with PCOS, an abnormally elevated epimerase enzyme converts excess MI to DCI in ovarian tissue, creating a localized MI deficit despite normal or even elevated systemic MI levels. Research by Unfer, Carlomagno, and colleagues established that supplementing the 40:1 MI:DCI ratio (rather than the physiological 100:1 ratio) produces superior clinical outcomes in PCOS — likely because the supplemental DCI compensates for systemic insulin resistance while the MI dose corrects the ovarian deficit. Multiple meta-analyses have confirmed the 40:1 combination superiority over MI alone for menstrual regularity and ovulation outcomes in PCOS patients.

Research: Unfer et al. (2017), Int J Endocrinol; Nordio & Proietti (2012), Eur Rev Med Pharmacol Sci.

PCOS and Ovarian Function

The evidence base for inositol in PCOS is substantial and growing. A 2019 Cochrane-style systematic review and meta-analysis by Pundir et al. in the American Journal of Obstetrics and Gynecology analyzed 13 randomized controlled trials and found that Myo-Inositol significantly improved clinical pregnancy rates, ovulation rates, and androgen profiles compared to placebo in women with PCOS. The 40:1 MI:DCI combination has been directly compared to metformin — the first-line pharmaceutical for PCOS insulin resistance — in multiple head-to-head trials. A 2017 RCT published in Gynecological Endocrinology found the 40:1 combination equivalent to metformin for reducing testosterone and improving menstrual regularity with fewer gastrointestinal side effects. A 2020 meta-analysis by Monastra et al. confirmed MI:DCI combination superiority over MI alone for oocyte quality and embryo development in PCOS patients undergoing assisted reproduction.

Research: Pundir et al. (2019), Am J Obstet Gynecol; Monastra et al. (2020), Nutrients; Unfer et al. (2017), Int J Endocrinol.

Depression and Mood Disorders

The psychiatric research on inositol began with the seminal observation by Barkai et al. (1978) that CSF inositol levels were significantly lower in depressed patients than controls. This led to a series of double-blind, placebo-controlled trials by Joseph Levine and colleagues at Ben Gurion University in the 1990s. Their landmark crossover trial (1995, American Journal of Psychiatry) found 12g/day Myo-Inositol significantly outperformed placebo on the Hamilton Depression Rating Scale after four weeks. A subsequent trial found equivalent efficacy between inositol and fluvoxamine (an SSRI) for depression at 6 weeks, with inositol producing significantly fewer side effects. The proposed mechanism is restoration of the PI second-messenger cycle that underlies serotonin, norepinephrine, and muscarinic receptor signal transduction — making inositol a “substrate” for these pathways rather than a direct receptor agonist or reuptake inhibitor.

Research: Levine et al. (1995), Am J Psychiatry; Levine et al. (1999), Eur Neuropsychopharmacol.

Panic Disorder and Anxiety

Inositol has demonstrated particular promise for panic disorder in controlled trials. Palatnik et al. (2001) published a double-blind crossover trial in the Journal of Clinical Psychopharmacology comparing 18g/day Myo-Inositol to fluvoxamine for panic disorder: inositol reduced panic attack frequency from 10 to 3.4 per week compared to a reduction from 10 to 5.4 per week with fluvoxamine, with the inositol group also experiencing significantly fewer side effects (nausea, fatigue). A separate Benjamin et al. trial (1995) found 18g/day inositol significantly reduced panic and agoraphobia scores compared to placebo in a four-week crossover trial. These findings suggest inositol may be particularly effective for panic, potentially due to the high density of PI-linked serotonin and norepinephrine receptors in amygdala and brainstem panic circuitry.

Research: Palatnik et al. (2001), J Clin Psychopharmacol; Benjamin et al. (1995), Am J Psychiatry.

Metabolic Health and Insulin Resistance

Myo-Inositol functions as a second messenger in insulin signaling: after insulin binds its receptor, Myo-Inositol phosphoglycans (MI-IPGs) are released and activate key metabolic enzymes including pyruvate dehydrogenase and glycogen synthase. When MI availability is insufficient, this second-messenger cascade is impaired — a mechanism implicated in insulin resistance independent of the insulin receptor itself. Controlled trials in women with gestational diabetes (Matarrelli et al., 2013) and in patients with metabolic syndrome have found 2–4g/day Myo-Inositol significantly improves fasting insulin, HOMA-IR (insulin resistance index), and fasting glucose compared to placebo. A 2018 systematic review in Nutrition journal analyzed 11 RCTs and concluded MI supplementation significantly reduced insulin resistance markers in insulin-resistant populations, including those with PCOS, gestational diabetes, and type 2 diabetes.

Research: Matarrelli et al. (2013), J Matern Fetal Neonatal Med; Croze & Soulage (2013), Biochimie.

PCOS and Hormonal Balance

• Evidence-based dose: 2,000–4,000mg Myo-Inositol + 50–100mg D-Chiro-Inositol (40:1 ratio) daily
• Timing: Split into two equal doses — morning and evening, ideally with meals
• Duration: Clinical trials typically run 3–6 months; menstrual cycle improvements often appear at 8–12 weeks
• Notes: Do not use high-dose DCI alone — excess DCI impairs oocyte quality; maintain the 40:1 ratio

Mood Support and Depression

• Research dose: 12,000mg (12g) Myo-Inositol daily, divided into 2–3 doses
• Timing: With meals to minimize GI side effects; split morning/afternoon/evening
• Practical note: Requires powder format — 12g as capsules (24 × 500mg capsules) is impractical
• Titration: Start at 2g daily and increase by 2g every 3–5 days to minimize osmotic GI side effects

Panic Disorder and Anxiety

• Research dose: 18,000mg (18g) Myo-Inositol daily for panic disorder
• Timing: Divided into 3 doses of 6g each with meals
• Notes: This dose is specific to panic disorder research — for general anxiety, lower doses (4–6g) may provide benefit
• Form required: Powder only — dissolve in water or juice for palatability

Metabolic Health and Insulin Sensitivity

• Evidence-based dose: 2,000–4,000mg Myo-Inositol daily
• Timing: With meals — particularly with higher-carbohydrate meals to support postprandial glucose metabolism
• Duration: Metabolic improvements in RCTs have been measured at 8–12 weeks; ongoing use supports sustained insulin sensitivity
• Notes: Pure MI is sufficient for metabolic applications; DCI combination not required unless PCOS is also present